Only 14 days of dosing
and done with ZURZUVAE1

A groundbreaking way to treat postpartum depression1

Explore dosing information, including recommendations for specific populations,
for ZURZUVAE® (zuranolone) treatment.

Dosing instructions are on the back
to help patients take ZURZUVAE

See back
Front of ZURZUVAE packaging for the 50 mg daily dose with a few blister pack capsules visible.
Back of ZURZUVAE blister pack demonstrating how each daily dose is clearly marked with dosing instructions.

For illustration purposes only.

What is the recommended dosage for ZURZUVAE?

50 mg orally once daily1

2 x 25 mg capsules
In the evening1
With fat-containing food1

400–1,000 calories;
25%–50% fat
For 14 days1

ZURZUVAE 25 mg National Drug Code (NDC):
64406-030-02

The safety and effectiveness of ZURZUVAE use beyond 14 days in a single treatment course have not been established.1

Dosage adjustments for specific populations1*

Patients who experience CNS
depressant effects within the 14-day period

Consider dose reduction to 40 mg (2 x 20 mg capsules) for the duration of the treatment course or discontinue therapy
NDC: 64406-029-01

Taking strong CYP3A4 inhibitors

30 mg (1 x 30 mg capsule)
NDC: 64406-031-01

Taking CYP4A4 inducers

Avoid concomitant use

With severe hepatic impairment

(Child-Pugh C)

Mild or moderate hepatic impairment (Child-Pugh A or B): no recommended dosage adjustment

30 mg (1 x 30 mg capsule)
NDC: 64406-031-01

With moderate or severe renal impairment

(eGFR <60 mL/min/1.73 m2)

Mild renal impairment (eGFR 60 to 89 mL/min/1.73 m2): no recommended dosage adjustment

30 mg (1 x 30 mg capsule)
NDC: 64406-031-01

*ZURZUVAE is recommended to be taken orally once daily in the evening with fat-containing food for 14 days.1

ZURZUVAE is available as 20 mg, 25 mg, and 30 mg capsules.1

Can ZURZUVAE be used with another oral antidepressant?

ZURZUVAE can be used alone or as an adjunct to oral antidepressant therapy.1

What should your patients do if they miss a dose?

If your patients miss a dose of ZURZUVAE, have them take the next dose at the regular time the following evening and not take extra capsules on the same day to make up for the missed dose. Advise them to continue taking ZURZUVAE until the treatment course is completed.1

What is the process for adjusting prescriptions?

If your patients need a lower dose of ZURZUVAE, the specialty pharmacy will provide dosing adjustment assistance.
Call 1-844-987-9882 with any questions.
Access the full dosing and prescribing guide
Download

How to prescribe ZURZUVAE in your electronic health record for patients with PPD

ZURZUVAE 25 mg NDC: 64406-030-02

Form field Form field & entry

Entry (Select click to see more detail to see more details)

Product

ZURZUVAE 50 mg (2 x 25 mg capsules daily) comes as a blister pack

ZURZUVAE 25 MG PO CAPS

Dose

Specify the dose. The 50 mg dose is taken as 2 x 25 mg capsules

25 mg

Route

Oral

Frequency

Once daily

Dispense quantity

Indicate the number of capsules

28 capsules

Patient sig

Add directions for how and when to take the medication

Take 2 capsules orally, once a day in the evening,
with fat-containing food, for 14 days

Notes

Diagnosis: Postpartum depression (ICD-10 code, F53.0)2

Explore types of patients with postpartum depression who may benefit from ZURZUVAE

Discover patient profiles

Learn about the 3 steps needed to start your patients with PPD on ZURZUVAE

How to get patients started
Sign up to receive more information about ZURZUVAE or request live support
Request information

References: 1. ZURZUVAE Prescribing Information. Cambridge, MA: Biogen and Sage Therapeutics, Inc. 2. ICD-10-CM Tabular List of Diseases and Injuries. Centers for Medicare & Medicaid Services. Last updated February 1, 2024. https://www.cms.gov/medicare/coding-billing/icd-10-codes/2024-icd-10-cm. Accessed August 8, 2024.

INDICATION

ZURZUVAE® (zuranolone) is indicated for the treatment of postpartum depression (PPD) in adults.

 

IMPORTANT SAFETY INFORMATION

 

WARNING: IMPAIRED ABILITY TO DRIVE OR ENGAGE IN OTHER POTENTIALLY HAZARDOUS ACTIVITIES

ZURZUVAE causes driving impairment due to central nervous system (CNS) depressant effects.

Advise patients not to drive or engage in other potentially hazardous activities until at least 12 hours after ZURZUVAE administration for the duration of the 14-day treatment course. Inform patients that they may not be able to assess their own driving competence, or the degree of driving impairment caused by ZURZUVAE.

 

WARNINGS AND PRECAUTIONS

 

Impaired Ability to Drive or Engage in Other Potentially Hazardous Activities

  • ZURZUVAE causes driving impairment due to central nervous system (CNS) depressant effects
  • Advise patients not to drive a motor vehicle or engage in other potentially hazardous activities requiring complete mental alertness, such as operating machinery, until at least 12 hours after ZURZUVAE administration for the duration of the 14-day treatment course. Inform patients that they may not be able to assess their own driving competence or the degree of driving impairment caused by ZURZUVAE

Central Nervous System Depressant Effects

  • ZURZUVAE can cause CNS depressant effects such as somnolence and confusion
  • Somnolence developed in 36% of patients who received ZURZUVAE (50 mg) and in 6% of patients who received placebo daily. Some ZURZUVAE-treated patients developed confusional state. One of these cases was severe, and was also associated with somnolence, dizziness, and gait disturbance
  • A higher percentage of ZURZUVAE-treated patients, compared to placebo-treated patients, experienced somnolence, dizziness, or confusion that required dosage reduction, interruption, or discontinuation
  • Because ZURZUVAE can cause CNS depressant effects, patients may be at higher risk of falls
  • Other CNS depressants such as alcohol, benzodiazepines, opioids, tricyclic antidepressants, or drugs that increase zuranolone concentration, may increase impairment of psychomotor performance or CNS depressant effects such as somnolence, cognitive impairment, and the risk of respiratory depression in ZURZUVAE-treated patients
  • To reduce the risk of CNS depressant effects and/or mitigate CNS depressant effects that occurs with ZURZUVAE treatment:
    • If patients develop CNS depressant effects, consider dosage reduction or discontinuation of ZURZUVAE
    • If use with another CNS depressant is unavoidable, consider dosage reduction
    • Reduce the ZURZUVAE dosage in patients taking strong CYP3A4 inhibitors
 

Suicidal Thoughts and Behavior

  • In pooled analyses of placebo-controlled trials of chronically administered antidepressant drugs (SSRIs and other antidepressant classes) that included approximately 77,000 adult patients and 4,500 pediatric patients, the incidence of suicidal thoughts and behaviors in antidepressant-treated patients age 24 years and younger was greater than in placebo-treated patients. There was considerable variation in risk of suicidal thoughts and behaviors among drugs, but there was an increased risk identified in young patients for most drugs studied. There were differences in absolute risk of suicidal thoughts and behaviors across the different indications, with the highest incidence in patients with major depressive disorder (MDD)
  • ZURZUVAE does not directly affect monoaminergic systems. Consider changing the therapeutic regimen, including discontinuing ZURZUVAE, in patients whose depression becomes worse or who experience emergent suicidal thoughts and behaviors

Embryo-fetal Toxicity

  • Based on findings from animal studies, ZURZUVAE may cause fetal harm when administered to a pregnant woman
  • Advise a pregnant woman of the potential risk to an infant exposed to ZURZUVAE in utero. Advise females of reproductive potential to use effective contraception during treatment with ZURZUVAE and for one week after the final dose
 

ADVERSE REACTIONS

 
  • The most common adverse reactions (≥5% and greater than placebo) in ZURZUVAE-treated patients were somnolence, dizziness, diarrhea, fatigue, nasopharyngitis, and urinary tract infection

 

DRUG INTERACTIONS

 

CNS Depressant Drugs and Alcohol

  • Caution should be used when ZURZUVAE is administered in combination with other CNS drugs or alcohol. If use with another CNS depressant is unavoidable, consider dosage reduction

Strong CYP3A4 Inhibitors

  • Reduce the ZURZUVAE dosage when used with a strong CYP3A4 inhibitor

CYP3A4 Inducers

  • Avoid concomitant use of ZURZUVAE with CYP3A4 inducers
 

USE IN SPECIFIC POPULATIONS

Pregnancy

  • There is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to antidepressants, including ZURZUVAE, during pregnancy. Healthcare providers are encouraged to register patients by calling the National Pregnancy Registry for Antidepressants at 1-844-405-6185 or visiting online at https://womensmentalhealth.org/research/pregnancyregistry/antidepressants/
  • Based on findings from animal studies, ZURZUVAE may cause fetal harm. Advise pregnant women of the potential risk to a fetus. Available data on ZURZUVAE use in pregnant women from the clinical development program are insufficient to evaluate for a drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes

Lactation

  • Available data from a clinical lactation study in 14 women indicate that zuranolone is present in low levels in human milk. There are no data on the effects of zuranolone on a breastfed infant and limited data on the effects on milk production
  • The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for ZURZUVAE and any potential adverse effects on the breastfed child from ZURZUVAE or from the underlying maternal condition

Hepatic Impairment

  • The recommended ZURZUVAE dosage in patients with severe hepatic impairment (Child-Pugh C) is lower than patients with normal hepatic function

Renal Impairment

  • The recommended ZURZUVAE dosage in patients with moderate and severe renal impairment is lower than those with normal renal function
 

DRUG ABUSE AND DEPENDENCE

 
  • ZURZUVAE contains zuranolone, a Schedule IV controlled substance
  • Zuranolone has abuse potential with associated risks of misuse, abuse, and substance use disorder including addiction
  • ZURZUVAE may produce physical dependence
 
 

Please see full Prescribing Information, including Boxed Warning.

 
Terms of Use Notice to CA Residents Privacy Policy Contact Us Cookie Policy Unsubscribe

SAGE THERAPEUTICS, the SAGE THERAPEUTICS logo, and ZURZUVAE are registered trademarks of Sage Therapeutics, Inc. BIOGEN and the BIOGEN logo are registered trademarks of Biogen Inc. The ZURZUVAE logo is a trademark of Sage Therapeutics, Inc. All other trademarks referenced herein are the property of their respective owners.

© 2024 Biogen. All rights reserved. ZUR-US-0299v3 11/24

© 2024 Biogen. All rights reserved. ZUR-US-0300v3 11/24